|
Convertible Securities - Additional Information (Detail) (USD $)
|
3 Months Ended | 6 Months Ended | 6 Months Ended | 1 Months Ended | 1 Months Ended | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Jun. 30, 2012
|
Jun. 30, 2012
|
Jun. 30, 2012
Secured Promissory Note
Installment
|
Dec. 31, 2011
Secured Promissory Note
|
Jun. 30, 2012
Secured Promissory Note
Promissory Notes Payable One
|
Jun. 30, 2012
Secured Promissory Note
Promissory Notes Payable One
Series GG Warrants
|
Jun. 30, 2012
Secured Promissory Note
Promissory Notes Payable One
Upon FDA approval of Lymphoseek
|
Jun. 30, 2012
Secured Promissory Note
Promissory Notes Payable One
Potentially available on terms to be negotiated
|
Jun. 30, 2012
Secured Promissory Note
Promissory Notes Payable Two
At the time of product registration or upon commercial sales
|
May 31, 2011
Series B Preferred Stock
|
Jun. 30, 2012
Series B Preferred Stock
|
Dec. 31, 2011
Series B Preferred Stock
|
|
| Debt Instrument | ||||||||||||
| Number of shares of convertible preferred stock converted | 917 | |||||||||||
| Number of common stock issued up on conversion | 2,998,590 | |||||||||||
| Preferred stock, shares outstanding | 9,083 | 9,083 | ||||||||||
| Number of common stock issuable up on future conversion | 29,701,410 | 29,701,410 | ||||||||||
| Loan Agreement, maximum borrowing capacity | $ 10,000,000 | $ 7,000,000 | $ 3,000,000 | |||||||||
| Debt instrument, interest rate | 6.75% | |||||||||||
| Debt instrument, effective interest rate | 10.00% | |||||||||||
| Warrants to purchase common stock, shares | 17,500,000 | 17,500,000 | 333,333 | |||||||||
| Warrants to purchase common stock, exercise price | 2.10 | |||||||||||
| Warrants to purchase common stock, expiration period | 2016-12 | |||||||||||
| Principal and interest, monthly installments period | 30 | |||||||||||
| Debt instrument, maturity date | Dec. 01, 2014 | |||||||||||
| Debt instrument, conversion face amount | 1,500,000 | |||||||||||
| Convertible debt, fixed conversion price | $ 2.77 | |||||||||||
| Option to convert debt to common stock beneficial conversion feature | 1,500,000 | 24,888 | ||||||||||
| Amortization of the debt discounts and deferred financing costs | $ 144,000 | $ 260,000 | ||||||||||